IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨

doi:10.19439/j.sjos.2021.05.002

上海口腔医学 ›› 2021, Vol. 30 ›› Issue (5): 456-461.doi: 10.19439/j.sjos.2021.05.002

IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨

谢非, 秦星, 童桐, 蒋英英, 张建军

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-05-28 修回日期:2020-06-28 出版日期:2021-10-25 发布日期:2021-11-08
通讯作者: 张建军,E-mail:zjjshuobo@163.com
作者简介:谢非（1994-）,女,硕士研究生,E-mail:xiefeix@hotmail.com
基金资助:
国家自然科学基金（81972573、81772933）; 上海市科学技术委员会科研计划项目（18JC1413700）; 上海高水平地方高校创新团队

Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma

XIE Fei, QIN Xing, TONG Tong, JIANG Ying-ying, ZHANG Jian-jun

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2020-05-28 Revised:2020-06-28 Online:2021-10-25 Published:2021-11-08

摘要/Abstract

摘要： 目的: 探讨IGF2BP1在口腔鳞癌细胞顺铂耐药中的作用和机制。方法: 运用小剂量间歇诱导法诱导顺铂敏感的口腔鳞癌细胞HN30,建立顺铂耐药口腔鳞癌细胞系HN30/DDP。通过蛋白免疫印迹方法检测亲本株与耐药株的IGF2BP1表达差异;利用siRNA和慢病毒过表达载体分析IGF2BP1基因表达水平降低或升高对癌细胞顺铂耐药的影响;应用MTT法检测IGF2BP1基因降低或升高后口腔鳞癌细胞对顺铂的IC₅₀。采用SPSS 17.0软件包对数据进行统计学分析。结果: 成功建立顺铂耐药的口腔鳞癌细胞系HN30/DDP,耐药细胞株较亲本株的耐药性明显提高。敲低HN30/DDP中的 IGF2BP1 表达水平,细胞耐药性降低;反之,亲本株细胞过表达 IGF2BP1后,细胞耐药性提高。Akt 信号通路活化是介导 IGF2BP1 促进口腔鳞癌细胞顺铂耐药的关键因素。结论: IGF2BP1 与口腔鳞癌的顺铂耐药密切相关。IGF2BP1 可通过激活下游 Akt 信号通路,促进口腔鳞癌细胞耐药。

关键词: 口腔鳞癌, IGF2BP1, 化疗耐药, 顺铂

Abstract: PURPOSE: This study focused on the role and mechanism of IGF2BP1 in cell cisplatin resistance of oral squamous cell carcinoma. METHODS: Low-dose intermittent induction method was used to induce cisplatin-sensitive oral squamous cell carcinoma cell line HN30, and establish cisplatin-resistant cell line HN30/DDP. Western blot was used to detect the protein expression level of IGF2BP1 in parental and resistant cell line. Knockdown or overexpression of IGF2BP1 by RNAi and lentivirus transfection method was utilized to analyze the effect of decreased or increased the gene expression of IGF2BP1 on cisplatin resistance. MTT method was used to detect the change of IC₅₀. Statistical analysis of data was performed using SPSS 17.0 software package. RESULTS: Cisplatin-resistant oral squamous cell carcinoma cell line was successfully established. The IC₅₀ of the drug-resistant cells was significantly higher than that of the parental cells. Knocking down the expression level of IGF2BP1 in drug-resistant strains reduced cell resistance; on the contrary, after overexpression of IGF2BP1 in parental cells dramatically increased cisplatin resistance. Mechanically, activation of Akt signaling pathway was the key factor mediating IGF2BP1 to promote cisplatin resistance in oral squamous cell carcinoma. CONCLUSIONS: IGF2BP1 is significantly associated with cisplatin resistance in oral squamous cell carcinoma. IGF2BP1 can promote cisplatin resistance of oral squamous cells by activating downstream Akt signaling pathway.

Key words: Oral squamous cell carcinoma, IGF2BP1, Chemotherapy resistance, Cisplatin

中图分类号:

R739.8

谢非, 秦星, 童桐, 蒋英英, 张建军. IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨[J]. 上海口腔医学, 2021, 30(5): 456-461.

XIE Fei, QIN Xing, TONG Tong, JIANG Ying-ying, ZHANG Jian-jun. Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2021, 30(5): 456-461.

参考文献

[1] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[3] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[4] Chi AC, Day TA, Neville BW.Oral cavity and oropharyngeal squamous cell carcinoma-an update[J]. CA Cancer J Clin, 2015, 65(5): 401-421.
[5] 邱蔚六. 口腔颌面部癌瘤治疗的新理念—浅析综合序列治疗[J]. 上海第二医科大学学报, 2005, 25(4): 321-324,358.
[6] 温玉明, 华成舸, 王昌美, 等. 口腔癌的综合治疗[J]. 中华口腔医学杂志, 2003, 38(1): 73-75.
[7] Huang X, Zhang H, Guo X, et al.Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer[J]. J Hematol Oncol, 2018, 11(1): 88.
[8] Bell JL, Turlapati R, Liu T, et al.IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma[J]. J Clin Oncol, 2015, 33(11): 1285-1293.
[9] Wan BS, Cheng M, Zhang L.Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer[J]. World J Gastroenterol, 2019, 25(40): 6063-6076.
[10] Elcheva IA, Wood T, Chiarolanzio K, et al.RNA-binding protein IGF2BP1 maintains leukemia stem cell properties by regulating HOXB4, MYB, and ALDH1A1[J]. Leukemia, 2019, 34(5): 1354-1363
[11] Müller S, Glaβ M, Singh AK, et al.IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner[J]. Nucleic Acids Res, 2019, 47(1): 375-390.
[12] Liu Z, Wu G, Lin C, et al.IGF2BP1 over-expression in skin squamous cell carcinoma cells is essential for cell growth[J]. Biochem Biophys Res Commun, 2018, 501(3): 731-738.
[13] Shi R, Yu X, Wang Y, et al.Expression profile, clinical significance, and biological function of insulin-like growth factor 2 messenger RNA-binding proteins in non-small cell lung cancer[J]. Tumour Biol, 2017, 39(4): 1010428317695928.
[14] Gong F, Ren P, Zhang Y, et al.MicroRNAs-491-5p suppresses cell proliferation and invasion by inhibiting IGF2BP1 in non-small cell lung cancer[J]. Am J Transl Res, 2016, 8(2): 485-495.
[15] Rebucci M, Sermeus A, Leonard E, et al.miRNA-196b inhibits cell proliferation and induces apoptosis in HepG2 cells by targeting IGF2BP1[J]. Mol Cancer, 2015, 14(1): 79-85.
[16] Qin X, Sun L, Wang J.Restoration of microRNA-708 sensitizes ovarian cancer cells to cisplatin via IGF2BP1/Akt pathway[J]. Cell Biol Int, 2017, 41(10): 1110-1118.
[17] Faye MD, Beug ST, Graber TE, et al.IGF2BP1 controls cell death and drug resistance in rhabdomyosarcomas by regulating translation of cIAP1[J]. Oncogene, 2015, 34(12): 1532-1541.
[18] Galanski M.Recent developments in the field of anticancer platinum complexes[J]. Recent Pat Anticancer Drug discov, 2006, 1(2): 285-295.
[19] Dasari S, Tchounwou PB.Cisplatin in cancer therapy: molecular mechanisms of action[J]. Eur J Pharmacol, 2014, 740: 364-378.
[20] Shen DW, Pouliot LM, Hall MD, et al.Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes[J]. Pharmacol Rev, 2012, 64(3): 706-721.
[21] Scanlon KJ, Kashani-Sabet M, Tone T, et al.Cisplatin resistance in human cancers[J]. Pharmacol Ther, 1991, 52(3): 385-406.
[22] Crul M, Schellens JH, Beijnen JH, et al.Cisplatin resistance and DNA repair[J]. Cancer Treat Rev, 1997, 23(5-6): 341-366.
[23] Galluzzi L, Senovilla L, Vitale I, et al.Molecular mechanisms of cisplatin resistance[J]. Oncogene, 2012, 31(15): 1869-1883.
[24] Wang SS, Lv Y, Xu XC, et al.Triptonide inhibits human nasopharyngeal carcinoma cell growth via disrupting Lnc-RNA THOR-IGF2BP1 signaling[J]. Cancer Lett, 2019, 443: 13-24.
[25] Kim T, Havighurst T, Kim K, et al.Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF inhibitors[J]. Mol Carcinog, 2018, 57(5): 678-683.
[26] Ali AY, Farrand L, Kim JY, et al.Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum[J]. Ann N Y Acad Sci, 2012, 1271(1): 58-67.
[27] Fraser M, Bai T, Tsang BK.Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function[J]. Int J Cancer, 2008, 122(3): 534-546.
[28] Fraser M, Leung B M, Yan X, et al.p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells[J]. Cancer Res, 2003, 63(21): 7081-7088.
[29] Freudlsperger C, Horn D, Weiβfuβ S, et al.Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma[J]. Int J cancer, 2015, 136(12): 2775-2785.
[30] Avan A, Narayan R, Giovannetti E, et al.Role of Akt signaling in resistance to DNA-targeted therapy[J]. World J Clin Oncol, 2016, 7(5): 352-369.
[31] Sun D, Wang J, Zhang H, et al.MK2206 Enhances cisplatin-induced cytotoxicity and apoptosis in testicular cancer through Akt signaling pathway inhibition[J]. Transl Oncol, 2020, 13(7): 100769.
[32] Sun D, Sawada A, Nakashima M, et al. MK2206 potentiates cisplatin-induced cytotoxicity and apoptosis through an interaction of inactivated Akt signaling pathway [J]. Urol Oncol, 2015, 33(3): 111.e117-111.e126.

IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨

Insight into the role of IGF2BP1 in drug resistant mechanism of oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	董淋升, 唐进, 程维, 冉婧璇, 刘兆博, 李雅冬. IL-6和β-catenin在口腔鳞癌中的表达及预后价值[J]. 上海口腔医学, 2023, 32(3): 280-286.
[2]	胡小媛, 王宁, 张晓野, 杨茜, 高菲, 王成勤, 尚伟, 项锋钢, 冯元勇. Chemerin对口腔鳞癌中性粒细胞浸润的影响及机制探讨[J]. 上海口腔医学, 2023, 32(2): 158-165.
[3]	郭梦瑶, 李凯玉, 聂敏海, 刘旭倩. 上调Decorin对口腔鳞癌荷瘤裸鼠EGFR、C-Myc、p21表达的影响[J]. 上海口腔医学, 2023, 32(1): 40-46.
[4]	文旭涛, 马振, 张翀, 陶识丞, 陈兴金, 麦华明. 不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响[J]. 上海口腔医学, 2022, 31(4): 343-348.
[5]	秦志明, 揭伟萍, 池彦廷, 李宏锋, 李斌斌. 基于局部可变阈值的无监督定量Ki-67细胞增殖指数模型的初步建立[J]. 上海口腔医学, 2022, 31(3): 248-254.
[6]	买尔哈巴·买合木提, 拜婕, 如斯坦木·依米提, 姚志涛. 50例口腔鳞癌患者治疗过程中营养状况改变及影响因素分析[J]. 上海口腔医学, 2022, 31(2): 205-210.
[7]	谈亦然, 赵铜超, 琚梧桐, 钟来平. 长春新碱对口腔鳞癌中Stathmin调控作用的实验研究[J]. 上海口腔医学, 2022, 31(1): 1-5.
[8]	李蕾, 李晓东, 庄乾伟, 葛良玉, 李志萍, 顾倩平, 白玉婷, 孟箭. 超声热疗联合TPF化疗治疗19例老年晚期口腔鳞癌的疗效分析[J]. 上海口腔医学, 2021, 30(5): 543-547.
[9]	邵小钧, 朱乔, 刘有, 韩小东, 林小臻, 席庆. 咀嚼槟榔与口腔鳞癌的相关临床病理学因素分析[J]. 上海口腔医学, 2021, 30(3): 268-272.
[10]	薛佳艺, 朱晓燕, 危常磊, 孙培, 张慧, 邓婧. 25例口腔鳞癌患者唾液代谢组学分析[J]. 上海口腔医学, 2021, 30(2): 201-205.
[11]	王树斌, 秦帅华, 易雅群, 李新明. 216例口腔鳞癌患者术后心理困扰影响因素及放疗前、后生存质量评价[J]. 上海口腔医学, 2021, 30(1): 71-76.
[12]	傅宗云, 陶峰. MMP-14、ING4和HIF-1α在60例口腔鳞癌中的表达及临床意义[J]. 上海口腔医学, 2020, 29(6): 642-646.
[13]	王学梅, 蒋勇. 双硫仑对口腔鳞癌细胞上皮-间充质转化的影响及机制探讨[J]. 上海口腔医学, 2020, 29(2): 138-145.
[14]	刘族志, 赵永兴, 林建能, 周国平. 双氢青蒿素对人口腔鳞癌细胞KBV200多药耐药的影响[J]. 上海口腔医学, 2019, 28(6): 586-590.
[15]	丁红忠, 许从平, 周永敏. 晚期口腔鳞癌患者独立预后因素及生存预测模型的建立[J]. 上海口腔医学, 2019, 28(5): 536-540.